AOTI, Inc., which describes itself as the Market Leader in topical oxygen therapy, reported double-digit Revenue growth in its 2026 interim results, published on 30 September 2026, while investors continue to watch progress on a proposed Medicare coverage policy that the company believes could substantially expand its market.

What the company does

AOTI develops and supplies TWO2 therapy, a topical oxygen treatment for chronic wounds such as diabetic foot ulcers. The company is US-focused and its shares trade on AIM in London. Its commercial model depends heavily on reimbursement from US public and private payers, which makes regulatory coverage decisions central to its prospects.

Latest developments

On 27 August 2026 AOTI reported positive feedback from a virtual public meeting on a proposed Local Coverage Determination for topical oxygen therapy issued by the Durable Medical Equipment Medicare Administrative Contractors. The company said commenters at the meeting unanimously supported the proposed criteria, which would establish coverage for Medicare beneficiaries with diabetic foot ulcers after four weeks of optimised standard care. The formal public comment period closed on 5 September 2026, and such determinations are generally expected to be finalised within 365 days, although no specific date has been given.

Earlier in the year, AOTI announced what it called a transformational milestone in July 2026, alongside a trading statement, and in April it published a real-world study of TWO2 therapy's effectiveness in chronic wound healing. The interim summary noted that the company holds Medicaid provider identifiers in 27 states. Its most recent announcement, on 4 November 2026, related to a director's shareholding.

Financial and Dividend picture

For the six months to 30 June 2026, reported revenue rose 10.8% to US$35.3m. Excluding Arizona Medicaid, underlying revenue grew 18.8% to US$31.9m. EBITDA increased 16.6% to US$3.6m, and the company generated positive Operating Cash Flow of US$0.9m, compared with an outflow a year earlier. Net Debt stood at US$6.3m at 30 June 2026. The published summary did not set out profit after tax, gross Margin or formal guidance, and no dividend was referred to. The group remains in a growth phase, and reinvestment in sales capacity is likely to take priority over Shareholder distributions.

Sector and index context

AOTI is one of a relatively small number of US medical technology companies listed on AIM, and one of the healthcare names in the FTSE AIM All Share Index. Wound care is a large and costly area for health systems, and companies that can demonstrate clinical and economic outcomes are well placed when payers review coverage. The read-across to peers depends largely on how US reimbursement evolves, and on whether investors in London continue to support US-focused growth companies that have chosen AIM rather than a domestic American listing for their equity.

Key risks

The most significant uncertainty is the timing and final wording of the Medicare coverage determination; a delay or narrower criteria than proposed would affect the size of the opportunity. Revenue from individual state Medicaid programmes can fluctuate, as the separate treatment of Arizona Medicaid in the interim figures illustrates. The company also carries net debt and operates in a competitive wound care market where clinical evidence and payer acceptance are essential.

What to watch next

Key milestones include finalisation of the Local Coverage Determination, further Medicaid and commercial payer wins, and the next trading update, which should show whether the faster underlying growth seen in the first half has been sustained into the second half of the year.